Steris (NYSE:STE) Price Target Raised to C$16.00

Steris (NYSE:STE) had its price objective upped by TD Securities from C$14.00 to C$16.00 in a report issued on Thursday, November 9th, StockTargetPrices.com reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other brokerages have also recently issued reports on STE. KeyCorp reiterated an overweight rating and set a $101.00 target price (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research upgraded Steris from a hold rating to a buy rating and set a $101.00 price target for the company in a report on Monday, October 9th. Raymond James Financial upped their target price on Steris from $95.00 to $100.00 and gave the company an outperform rating in a research report on Monday, October 16th. Finally, BidaskClub lowered Steris from a strong-buy rating to a buy rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $77.80.

Steris (NYSE STE) opened at $88.93 on Thursday. Steris has a one year low of $64.37 and a one year high of $93.39. The firm has a market cap of $7,580.00, a PE ratio of 22.80 and a beta of 1.31. The company has a quick ratio of 2.18, a current ratio of 2.80 and a debt-to-equity ratio of 0.48.

Steris (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the consensus estimate of $0.95 by ($0.01). Steris had a net margin of 5.59% and a return on equity of 11.49%. The business had revenue of $634.20 million during the quarter, compared to analysts’ expectations of $629.02 million. During the same quarter last year, the firm earned $0.89 EPS. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. equities analysts expect that Steris will post 4.06 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be paid a dividend of $0.31 per share. The ex-dividend date is Tuesday, November 21st. This represents a $1.24 annualized dividend and a yield of 1.39%. Steris’s dividend payout ratio is currently 73.81%.

In other news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $90.50, for a total transaction of $905,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard Martin Steeves sold 156,072 shares of the stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $87.13, for a total value of $13,598,553.36. Following the transaction, the director now directly owns 9,362 shares in the company, valued at approximately $815,711.06. The disclosure for this sale can be found here. Insiders have sold 192,722 shares of company stock valued at $16,913,753 in the last ninety days. Company insiders own 2.55% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP acquired a new stake in Steris in the 3rd quarter valued at approximately $284,000. Neuberger Berman Group LLC lifted its position in shares of Steris by 10.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,083 shares of the medical equipment provider’s stock worth $803,000 after acquiring an additional 886 shares during the period. California Public Employees Retirement System lifted its position in shares of Steris by 7.1% in the 3rd quarter. California Public Employees Retirement System now owns 211,344 shares of the medical equipment provider’s stock worth $18,683,000 after acquiring an additional 14,062 shares during the period. Zions Bancorporation bought a new stake in shares of Steris in the 3rd quarter worth approximately $178,000. Finally, Vident Investment Advisory LLC bought a new position in shares of Steris during the 3rd quarter worth approximately $952,000. 89.44% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Steris (NYSE:STE) Price Target Raised to C$16.00” was first published by BBNS and is owned by of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/td-securities-boosts-steris-plc-ste-price-target-to-c16-00/1771887.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Stock Target Prices

Analyst Recommendations for Steris (NYSE:STE)

Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.